Immucor Announces Fiscal Year 2009 Revenue and Earning...( NORCROSS Ga. June 4 /- Immucor In...)

NORCROSS, Ga., June 4 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced revenue and earnings guidance for the fiscal year ending May 31, 2009.

For fiscal year 2009:

-- The company expects revenues to range from $292 million to

$300 million.

-- Gross margin is expected to be in the range of 70% to 71%.

-- Net income is expected to be in the range of $80.0 million to

$83.0 million.

-- We expect to generate earnings per diluted share in the range of

$1.11 to $1.15.

We base our projections on our history of operations, the recurring nature of a significant portion of our revenues, including contractually committed purchases from large customers, and the predictability of our expenses through the fiscal year.

In making this projection, management has made the following assumptions:

-- With respect to revenues, the Company has extrapolated recent past

results and assumed the Company will generate additional revenues from

the implementation of our price strategy, the continuing sales of the

Galileo(R) and Echo(R) instruments in North America, Japan and Europe

and the reagent growth associated with these instrument placements.

-- With respect to the pending BioArray acquisition, the Company has

excluded the impact of the acquisition from these projections. As

previously announced the Company expects dilution of approximately

$0.20 to $0.23 in EPS in the first full year of operations following

closing, including approximately $0.05 per share of dilution resulting

from non-cash amortization expense.

-- With respect to stock based compensation expense, the Company expects

an increase of approximately $1.0 million.

Immucor, Inc. will host a confe
'/>"/>